Ophthotech Corp. (OPHT)

Trade OPHT now with
11/12/2018 7:31:43 AM Ophthotech Announces Results From Phase 2a Safety Trial Of Zimura In Combination With Lucentis
10/31/2018 6:42:56 AM Ophthotech Q3 Net Loss $14.7 Mln Or $0.41/Shr Vs Net Income $189.1 Mln Or $5.25/Shr Last Year
10/4/2018 7:41:30 AM Ophthotech Completes Patient Recruitment As Planned For Phase 2b Clinical Trial Of Zimura Monotherapy
8/22/2018 7:34:45 AM Ophthotech Says Scientific Data For Novel Adeno-Associated Virus Gene Therapy In RHO-adRP Published
8/1/2018 7:22:24 AM Ophthotech Q2 Net Loss $13.2 Mln Or $0.37/Shr Vs Net Loss $22.2 Mln Or $0.62/Shr Prior Year
7/10/2018 8:02:48 AM ElectroCore Appoints Carrie Cox As Chairman And Michael Atieh, Stephen Ondra As Recent Additions To Board
6/7/2018 7:06:39 AM Ophthotech Enters Into Gene Therapy Agreements With The University Of Florida And The University Of Pennsylvania
5/9/2018 7:21:05 AM Ophthotech Q1 Net Loss $13.1 Mln Or $0.36/Shr Vs Loss Of $43.1 Mln Or $1.20/Shr Last Year
5/1/2018 7:38:20 AM Ophthotech Reports Completion Of Patient Enrollment In Its Phase 2a Clinical Trial Of Zimura
2/27/2018 6:35:27 AM Ophthotech Targets Gene Therapy To Expand Its Orphan And Age-Related Retinal Disease Strategy
2/27/2018 6:35:01 AM Ophthotech Q4 Net Loss $9.5 Mln Or $0.26/shr Vs Loss Of $66.3 Mln Or $1.86/Shr Last Year
1/16/2018 7:30:36 AM Ophthotech Announces First Patient Enrolled In The Phase 2b Clinical Trial Of Zimura
1/16/2018 7:16:15 AM Ophthotech Elects Jane Pritchett Henderson, CFO And SVP Of Corporate Development At Voyager Therapeutics, To Board